Institutional members access full text with Ovid®

Rifaximin Receives New Indication

Aschenbrenner, Diane S. MS, APRN-BC

AJN, American Journal of Nursing: July 2010 - Volume 110 - Issue 7 - p 28
doi: 10.1097/01.NAJ.0000383928.15097.ad
Drug Watch

* Rifaximin (Xifaxan), a nonsystemic antibiotic usually used to treat traveler's diarrhea, has been approved for the prevention of recurrent hepatic encephalopathy in patients with chronic liver disease.

* The most common adverse effects of rifaximin are peripheral edema, nausea, gas, and headache.

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: dianea@son.jhmi.edu.

© 2010 Lippincott Williams & Wilkins, Inc.